Evidence map›Paper›PMID 23160988›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2013

Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels.

Eldo V Kuzhikandathil, Samantha Cote, Soumava Santra, Aloke K Dutta

Abstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The multifunctional dopamine DBioorganic & medicinal chemistry · 2020
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Eldo V KuzhikandathilDepartment of Pharmacology & Physiology, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA.
Samantha Cote
Soumava Santra
Aloke K Dutta
Rutgers, The State University of New Jersey · USEugene Applebaum College of Pharmacy and Health Sciences · USWayne State University · US

Funding

Novel Neuroprotective Treatment for Parkinson's DiseaseR01NS047198 · NINDS · WAYNE STATE UNIVERSITY · PI DUTTA, ALOKE K · 2005 to 2015
$3.7M
NINDS NIH HHS NS047198NINDS NIH HHS R01 NS047198
6 · The paper itself

Abstract

This study aims to determine the effect of the novel D(3) dopamine receptor agonist, D-264, on activation of D(3) and D(2) dopamine receptor signal transduction pathways and cell proliferation. AtT-20 neuroendocrine cells stably expressing human D(2S), D(2L), and D(3) dopamine receptors were treated with D-264 and the coupling of the receptors to mitogen-activated protein kinase (MAPK) and G protein-coupled inward rectifier potassium (GIRK) channels was determined using Western blotting and whole-cell voltage clamp recording, respectively. D-264 potently activated MAPK signaling pathway coupled to D(2S), D(2L), and D(3) dopamine receptors. The activation of MAPK was more pronounced than the reference agonist quinpirole and was longer lasting. D-264 also activated GIRK channels coupled to D(2S), D(2L), and D(3) receptors. In addition, D-264 dose-dependently induced cell proliferation in AtT-D(2L) and AtT-D(3) cells. These results indicate that D-264 robustly activates GIRK channels and MAPK coupled to D(2) and D(3) dopamine receptors in AtT-20 cells. D-264 is also a potent inducer of cell proliferation.

Indexed as

AnimalsBenzothiazolesBiphenyl CompoundsCell LineCell ProliferationCHO CellsCloning, MolecularCricetinaeCricetulusDopamine AgonistsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsHumansMiceMitogen-Activated Protein KinasesPiperazinesReceptors, Dopamine D2BenzothiazolesBiphenyl CompoundsDopamine AgonistsG Protein-Coupled Inwardly-Rectifying Potassium ChannelsMitogen-Activated Protein KinasesN(6)-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo(d)thiazole-2,6-diaminePiperazinesReceptors, Dopamine D2Receptors, Dopamine D3Thiazoles

Identifiers

PMID23160988
PMCPMC3560311
OpenAlexW2101407602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.